EIR Ventures
  • This is Eir Ventures
  • Team
  • Investments
  • Sustainability
  • News
  • Contact
    • Investor Login
    • Download
Select Page
Interview with Eir Ventures’ Magnus Persson in Dagens Industri

Interview with Eir Ventures’ Magnus Persson in Dagens Industri

by Thomas Rønn | Jan 25, 2021 | Other News

För 25 år sedan var han med och grundade Healthcap. Nu har Magnus Persson gjort det igen, med Eir Ventures, har han startat ett nytt bolag specialiserat på life science-investeringar. ”Sverige och Norden har länge visat sig fantastiskt när det gäller innovation”,...
Interview with Eir Ventures’ Stephan Christgau in NASDAQ newsletter

Interview with Eir Ventures’ Stephan Christgau in NASDAQ newsletter

by Thomas Rønn | Jan 23, 2021 | Articles

Q: Eir Ventures has now been in operations for 6 months since the launch last summer, how has that been? We were delighted to be able to reach the first close of Eir Ventures last summer. Obviously raising a new first time life science venture fund is never easy, and...
New Nordic Life Science Venture Fund, Eir Ventures, launched to leverage the untapped potential of Health Care Innovation

New Nordic Life Science Venture Fund, Eir Ventures, launched to leverage the untapped potential of Health Care Innovation

by Thomas Rønn | Jan 23, 2021 | Articles, Other News

Life sciences focused fund also announces first close of EUR76 million July 10, 2020, Stockholm & Copenhagen: Eir Ventures, a Nordic Life Science Venture Fund, today announced a first close of its new fund of EUR76 million. With a strong base in the Nordic region...
Eir Ventures completes seed-financing of Sortina Pharma with GU Ventures to develop breakthrough cancer treatments

Eir Ventures completes seed-financing of Sortina Pharma with GU Ventures to develop breakthrough cancer treatments

by Thomas Rønn | Jan 14, 2021 | Press Releases

Sortina Pharma AB today announces a financing led by the venture capital fund Eir Ventures and with GU Ventures, to unlock the potential of proprietary anti- sortilin cancer therapy to cure aggressive cancer. The founders of Sortina Pharma, Professor Göran Landberg...
Eir Ventures is delighted to announce our participation in the over subscribed €127M series B round in IO Biotech

Eir Ventures is delighted to announce our participation in the over subscribed €127M series B round in IO Biotech

by Thomas Rønn | Jan 13, 2021 | Press Releases

IO Biotech develops new cancer treatments, that have proven to give outstanding responses in combination with current standard of care in melanoma (skin cancer) and Non-small cell lung cancer. Eir Ventures is delighted to announce our participation in the over...
Eir Ventures have lead the funding round in Synklino, an innovative Biotech company that develops new first in class therapies for viral infections

Eir Ventures have lead the funding round in Synklino, an innovative Biotech company that develops new first in class therapies for viral infections

by Thomas Rønn | Sep 29, 2020 | Press Releases

Synklino is a Danish biotech company with technology from the University of Copenhagen and the Technical university of Denmark, focusing on developing groundbreaking therapies against devastating virus infections. Eir Ventures is happy to announce that we have lead...
Eir Ventures co-leads high profile syndicate in €55 million investment in Galecto Biotech

Eir Ventures co-leads high profile syndicate in €55 million investment in Galecto Biotech

by Thomas Rønn | Sep 25, 2020 | Press Releases

Eir Ventures co-leads high profile syndicate in €55 million investment in Galecto Biotech. The company is based on science and technology stemming from Swedish academia and developed in Denmark. The technology addresses fibrotic diseases with limited or no care...
New Nordic Life Science Venture Fund, Eir Ventures, launched to leverage the untapped potential of Health Care Innovation

New Nordic Life Science Venture Fund, Eir Ventures, launched to leverage the untapped potential of Health Care Innovation

by Thomas Rønn | Jul 10, 2020 | Press Releases

Life sciences focused fund also announces first close of EUR76 million July 10, 2020, Stockholm & Copenhagen: Eir Ventures, a Nordic Life Science Venture Fund, today announced a first close of its new fund of EUR76 million. With a strong base in the Nordic region...

Recent Posts

  • Eir Ventures celebrates 3 years anniversary
  • Lovisa Backemar new Principal.
  • Eir invests in RAPP
  • Eir invests in GutCRINE
  • Eir Ventures invests in Henlez

Recent Comments

    Get in Touch
    Eir Ventures is located in Stockholm, Sweden, and Copenhagen, Denmark.
    Sweden Office
    Grev Turegatan 27
    SE-114 38 Stockholm
    Sweden
    Denmark Office
    Havnegade 39
    DK-1058 Copenhagen
    Denmark
    Contact us
    info@eirventures.eu
    ©2021 Eir Ventures.